Mwanza Intervention Trials Unit
Mwanza, Tanzania
NCT Number: NCT04953130
Add-Vacc is an unblinded cluster-randomised trial (CRT) with two arms: (i) the national HPV vaccination programme (girls aged ~14 years, control arm) and (ii) the national programme plus single-dose male HPV vaccination given to a multi-year cohort of boys (intervention arm). The CRT will be conducted in 26 communities/clusters (13 per arm) in northern Tanzania. Boys aged 14 to 18 years in the intervention arm will receive one dose of the 4-valent HPV vaccine (Gardasil®) that protects against HPV 6, 11, 16, and 18. Population genital HPV prevalence in 18 to 21-year-olds will be compared between intervention clusters (female and male vaccination) and control clusters (female vaccination only) at 3 years after the intervention. Blood sampling for immune responses and adverse event data collection will be performed in a subset of 200 male subjects in selected intervention clusters.
This study is active but is not currently recruiting participants.
14 year–18 year
Male
Interventional
Phase 4
Mwanza, Tanzania
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Boys will be excluded from HPV vaccination if:
Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).
Other names: 4-valent HPV vaccine
Time frame: Month 36
Prevalence of 4-valent vaccine HPV genotype DNA (HPV 6, 11, 16 or 18) in males and females aged 18 to 21 years in intervention clusters and control clusters 36 months post-male vaccination
Time frame: Month 12, 24 and 36
Proportion seroconverting to, and geometric mean antibody titres (GMTs) for, HPV vaccine genotypes, and safety and tolerability (local and systemic adverse events), measured in a subset of 200 vaccinated boys
Time frame: Month 36
The proportion of females, and of males, aged 18 to 21 years in the control arm with detectable genital 4-valent HPV vaccine genotype DNA at baseline and at M36.
Time frame: Month 36
The proportion of females aged 16 years who received 1 dose of HPV vaccine (uptake) and who complete 2 doses (coverage) by arm at baseline and M36
Time frame: Month 24
Self-reported acceptability of and barriers to receiving male vaccination by community members and to delivering male HPV vaccination by health care workers (HCW)
Time frame: Month 36
Incremental cost-effectiveness ratio for single dose male vaccination plus existing female vaccination programme compared to female vaccination only
London School of Hygiene and Tropical Medicine
Other
Acronym: Add-Vacc
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06162676
Communicable Diseases, DNA Virus Infections
East Lansing, Michigan, United States
View Trial DetailsNCT06002126
Blood-Borne Infections, Cervical High Grade Squamous Intraepithelial Lesion
São Paulo, Brazil
View Trial DetailsNCT07202936
Communicable Diseases, DNA Virus Infections
Harare, Zimbabwe
View Trial DetailsNCT04255849
Communicable Diseases, DNA Virus Infections
São Paulo, Brazil
View Trial Details